Novo Nordisk’ chief executive Lars Fruergaard ... be the only industry representative in the GLP-1 agonist market to testify at the hearing. AstraZeneca's run of positive trial results with ...

Novo Nordisk's (NVO) investors are worried its competition ... according to the latest prescription data last month. But Novo CEO Lars Jørgensen attributes the softness in sales to the copycats ...

"We’re excited to work with Novo Nordisk, a company known for breakthrough innovation in clinical medicine and a strong portfolio of medications," Hims & Hers CEO Andrew Dudum said in a statement.

Novo Nordisk CEO Lars Jørgensen sits down for an interview with Yahoo Finance senior health reporter Anjalee Khemlani, where they discuss Novo's GLP-1 weight-loss drug Wegovy, the drugmaker's ...

Drugmaker Novo Nordisk NVO-N expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after ...